⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 22, 2024Journal of Clinical OncologyOpen Access

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Share

Abstract

The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Spigel et al. (2024) studied this question.

synapsesocial.com/papers/68e6e0a4b6db64358765ca6e https://doi.org/10.1200/jco.23.02110

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Signal pathways and precision therapy of small-cell lung cancerReview · 2022 · 137 citations
2Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung CancerRCT · 2006 · 650 citations
3RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancerLate-Phase Clinical Trial · 2022 · 19 citations
4Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANOriginal Research · 2022 · 352 citations
5Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization StrategyOriginal Research · 2006 · 385 citations